Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00699465
Other study ID # EUDRACT 2007-006206-24
Secondary ID
Status Recruiting
Phase Phase 4
First received June 12, 2008
Last updated July 1, 2010
Start date August 2008
Est. completion date December 2013

Study information

Verified date July 2010
Source University of Oulu
Contact Matti E Hillbom, MD, PhD
Phone 358-8-315-4518
Email matti.hillbom@oulu.fi
Is FDA regulated No
Health authority Finland: Finnish Medicines Agency
Study type Interventional

Clinical Trial Summary

- To evaluate the efficacy of using IPC during the acute phase of ICH in the prevention of VTE.

- To assess the safety and efficacy of additional therapy with enoxaparin.

- To compare the efficacy and safety of the European and American guideline recommendations.

- To provide an efficient and safe thromboprophylaxis for several weeks until the patient is able to walk.


Description:

- Although it has been poorly investigated, the risk of VTE among patients with acute primary intracerebral hemorrhage is generally believed to be at least as high as among patients with ischemic stroke.

- The currently available guidelines state that while low doses of subcutaneous heparin or low-molecular-weight heparin may reduce VTE, it is possible that their effect is counterbalanced by an increase in hemorrhagic complications.

- It is still unclear when (if ever) low-molecular-weight-heparin should be safely initiated in ICH patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 320
Est. completion date December 2013
Est. primary completion date July 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- acute primary ICH

- > 17 years

- unable to walk

- admitted within 12 h after onset of ICH

- informed consent obtained

Exclusion Criteria:

- other type of ICH than acute primary intracerebral hemorrhage

- patients who need neurosurgery

- evidence of VTE at screening

- thrombolytic treatment within the preceding week

- major surgery or major trauma within the preceding 3 months

- life expectancy less than 3 months due to comorbid disorders

- confirmed malignant disease (cancer)

- hepatitis and/or liver cirrhosis

- renal failure

- infectious disease (HIV, endocarditis etc.)

- current of previous hematologic disease

- recent active and untreated gastric/duodenal ulcer

- allergy or known hypersensitivity to enoxaparin or heparins

- known hypersensitivity to benzyl alcohol

- women of childbearing age if pregnant

- participation in another study within the preceding 30 days

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Intervention

Drug:
enoxaparin
20 mg enoxaparin (2 000 IU) s.c. will be given twice daily starting 24-48 h after onset of the stroke. Intermittent pneumatic compression will be started immediately after admission.
enoxaparin placebo
Placebo will be given s.c. twice daily starting 24-48 h after onset of the stroke for 2 days. Thereafter, 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily. Intermittent pneumatic compression will be started immediately after admission.

Locations

Country Name City State
Finland Department of Neurology, Oulu University Hospital Oulu

Sponsors (2)

Lead Sponsor Collaborator
University of Oulu Helsinki University

Country where clinical trial is conducted

Finland, 

References & Publications (2)

Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, Mayberg M, Morgenstern L, Ogilvy CS, Vespa P, Zuccarello M; American Heart Association; American Stroke Association Stroke Council; High Blood Pressure Research Council; Quality of Care and Outcomes in Research Interdisciplinary Working Group. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. 2007 Jun;38(6):2001-23. Epub 2007 May 3. — View Citation

Steiner T, Kaste M, Forsting M, Mendelow D, Kwiecinski H, Szikora I, Juvela S, Marchel A, Chapot R, Cognard C, Unterberg A, Hacke W. Recommendations for the management of intracranial haemorrhage - part I: spontaneous intracerebral haemorrhage. The European Stroke Initiative Writing Committee and the Writing Committee for the EUSI Executive Committee. Cerebrovasc Dis. 2006;22(4):294-316. Epub 2006 Jul 28. Erratum in: Cerebrovasc Dis. 2006;22(5-6):461. Katse, Markku [corrected to Kaste, Markku]. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The cumulative occurrence of confirmed VTE, defined as the composite of symptomatic or asymptomatic DVT, or symptomatic or fatal PE occurring during the treatment period. 90 days No
Secondary Bleeding complications including rebleedings occurring within the treatment period 90 days Yes
Secondary Increase in ICH volume observed by head CT or at autopsy during the treatment period 90 days Yes
Secondary Cardiovascular death occurring within the treatment period 90 days Yes
Secondary Death due to any cause occurring within the treatment period 90 days Yes
See also
  Status Clinical Trial Phase
Recruiting NCT05089331 - ROSE-Longitudinal Assessment With Neuroimaging
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Active, not recruiting NCT04522102 - Antiplatelet Secondary Prevention International Randomised Trial After INtracerebral haemorrhaGe (ASPIRING)-Pilot Phase Phase 3
Terminated NCT04178746 - PRONTO: Artemis in the Removal of Intraventricular Hemorrhage in the Hyper-Acute Phase
Not yet recruiting NCT03956485 - Multicentre Registry of Patients With Spontaneous Acute Intracerebral Hemorrhage in Catalonia (HIC-CAT).
Enrolling by invitation NCT02920645 - Multicenter Validation of the AVICH Score N/A
Recruiting NCT02625948 - Tranexamic Acid for Acute ICH Growth prEdicted by Spot Sign Phase 2
Completed NCT02478177 - Addressing Real-world Anticoagulant Management Issues in Stroke
Completed NCT01971359 - Clinical Outcomes Following Parafascicular Surgical Evacuation of Intracerebral Hemorrhage: A Pilot Study N/A
Completed NCT01261091 - Early Tracheostomy in Ventilated Stroke Patients N/A
Terminated NCT00990509 - Albumin for Intracerebral Hemorrhage Intervention Phase 2
Completed NCT00716079 - The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial N/A
Recruiting NCT00222625 - rFVIIa in ICH in Patients Treated With Anticoagulants or Anti-Platelets Phase 2
Recruiting NCT05095857 - The Anesthetic Ketamine as Treatment for Patients With Severe Acute Brain Injury Phase 4
Recruiting NCT04548596 - NOninVasive Intracranial prEssure From Transcranial doppLer Ultrasound Development of a Comprehensive Database of Multimodality Monitoring Signals for Brain-Injured Patients
Not yet recruiting NCT06429332 - International Care Bundle Evaluation in Cerebral Hemorrhage Research Phase 4
Recruiting NCT05492474 - Cranial Ultrasound for Prehospital ICH Diagnosis N/A
Not yet recruiting NCT05502874 - Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage
Recruiting NCT04604587 - MRI-visible Enlarged Perivascular Spaces and the Alteration of Lymphatic Drainage System in CAA Phase 3
Recruiting NCT05504941 - Detection of an Endovascular Treatment Target in Patients With an Acute, Spontaneous Intracerebral Hemorrhage N/A